Nice analysis of gastric NETs in Belgium by Marlies Maly with clear working points on pathology reporting, adequate staging and attention points for endoscopy#ENETS 2024🏹🏹

Great presentation by PhD student Dr Hannes Leupe on our novel and now clinically validated 18F-Octreotide PET tracer for SSTR. Thx to co-authors. Great closure of wonderfull theranostic session with 177Lu, alpha-emitters and novel targets! #ENETS2024

🌟 Day 3 at #ENETS2024: Prof Timon Vandamme explores the cutting-edge of PRRT in NET care. Discover the latest in treatment strategies and diagnostic imaging that are redefining patient outcomes. Dive into the full overview: bit.ly/3J7EghJ #NeuroendocrineTumours

🌟NETTER-2 Study shines at #ENETS2024: Prof Timon Vandamme reviews PRRT's unprecedented impact in high-grade NET treatment. A first in first-line care, revealing a path for enhanced patient outcomes. #NeuroendocrineTumours #OncologyResearch #MediMix

✅ Switching to 2nd line after #IO should be considered in toxicity or disease progression Do you know which 2nd line treatment options are approved in advanced #HCC? Watch the experts knowledge share by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇 ow.ly/7wYi50R46a5 #MedEd

Today is all about #neuroendocrinecancer at #ENDIMET2024, the largest medical conference in Colombia with 3000+ participants. Happy to be invited to talk about the NET treatment algorithm and the role of somatostatin analogues in grade 3 NET @aceendocrino #launiónhACElafuerza

Calling all early-career physicians and scientists passionate about advancing NET research! Join us for the NextGEN ENETS Scientific Workshop in Seville, Spain, from 30 Oct to 1 Nov 2024. Applications for grants now open until 20 June - so don't miss out! enets.org/grant/nextgen-…

🔥 What would you do in case of slow progression under #IO based treatment for a patient with advanced #HCC? Check out the interactive patient case video from Timon Vandamme to follow a patient's journey & discuss when to switch to 2nd line👇 ow.ly/h7KL50RuPcX #MedEd

Ga dit hier even achterlaten.

✅ TKIs are recommended treatments for #HCC patients who are not eligible for #IO first line Do know what patient groups this includes? Find out in the webinar replay of our experts knowledge share by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇 ow.ly/Qxnu50RUCNI #MedEd

Lack of awareness and management of conflict of interest among oncologists - splendid presentation by Khalid El Bairi on results of the ONCOTRUST-1 pilot study. Looking forward to ONCOTRUST-2. #globaloncology #ASCO24

CD40 agonist mitazalimab with mFOLFIRINOX in mPDAC. Promising data published in Lancet Oncol. We keep fighting against this disease. # ASCO24; Vall d’Hebron Institute of Oncology (VHIO) The Lancet Oncology

The patient voice was central to NET research priorities at an insightful conference on June 6th, in Bari, Italy on “The Biology, Diagnosis and Treatment of NETs: Current Understanding and Research Priorities”. 📌Read more: incalliance.org/net-research-c… #LetsTalkAboutNETs

First-line PRRT is going to be a great addition to the therapeutic armamentarium against NETs. Treatment personalization remains crucial to improve outcomes though rdcu.be/dNdwl nature.com/articles/s4157…

💡 There is a lack of solid evidence for optimal 2nd line regimens after progression of advanced #HCC Do you know what 2nd line treatment options have been approved? Find out in the webinar replay by Ducreux Michel, Timon Vandamme & Changhoon Yoo, MD👇 ow.ly/K4CR50Sz3Tj #MedEd #IO

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/

🚨 New Videos on PRRT for Neuroendocrine Tumors (NET)! Prof Chris Verslype, Prof Timon Vandamme & Prof Christophe Deroose discuss the latest breakthroughs in PRRT and future therapies like Actinium-225.

Hans Prenen #ESMO24 concomitant paper: Adrian Sacher, M.D. presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium Hans Prenen